Resmed Inc (RSMDF) — SEC Filings
Resmed Inc (RSMDF) — 26 SEC filings. Latest: 8-K (Nov 20, 2025). Includes 13 8-K, 6 10-Q, 2 DEF 14A.
Overview
Resmed Inc (RSMDF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 20, 2025: ResMed Inc. filed an 8-K on November 20, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits. Th
Sentiment Summary
Across 26 filings, the sentiment breakdown is: 3 bullish, 23 neutral. The dominant filing sentiment for Resmed Inc is neutral.
Filing Type Overview
Resmed Inc (RSMDF) has filed 13 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 DEFA14A, 2 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (26)
Risk Profile
Risk Assessment: Of RSMDF's 24 recent filings, 0 were flagged as high-risk, 4 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,335,582,000 |
| Net Income | $348,536,000 |
| EPS | $2.37 |
| Debt-to-Equity | 0.36 |
| Cash Position | $1,383,848,000 |
| Operating Margin | 33.4% |
| Total Assets | $8,308,352,000 |
| Total Debt | $668,560,000 |
Key Executives
- Michael "Mick" Farrell
- Christopher DelOrefice
- Nicole Mowad-Nassar
Industry Context
ResMed operates in the rapidly evolving medical device and digital health sectors, focusing on sleep-disordered breathing and other respiratory conditions. The industry is characterized by increasing demand for home-based care solutions, driven by aging populations and the prevalence of chronic respiratory diseases. Key trends include the integration of connected devices for remote patient monitoring, data analytics for personalized treatment, and the shift towards value-based healthcare models.
Top Tags
operations (5) · 10-Q (5) · financials (5) · financial-reporting (4) · executive-compensation (4) · corporate-governance (3) · Sleep Apnea (3) · medical-devices (3) · amendment (3) · shareholder-vote (2)
Executive Compensation
From the most recent DEF 14A filing (Oct 2, 2025):
- Michael J. Farrell — Chief Executive Officer: $12,600,000
- Robert L. (Rob) Cook — Chief Financial Officer: $5,500,000
- David P. (Dave) Weinstock — Chief Operating Officer: $5,200,000
- Reshma Gupta — Chief Business Unit Leader, Digital Health: $4,800,000
- Dwight G. (Dwight) DeLong — Chief Business Unit Leader, Sleep & Respiratory Care: $4,700,000
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-15317 | Identifies the company's filing history with the SEC. |
| EIN | 98-0152841 | Employer Identification Number for tax purposes. |
| Net Revenue | $1.34B | Increased 9.1% from $1.22B in Q1 2024 |
| Net Income | $348.5M | Increased 11.9% from $311.4M in Q1 2024 |
| Diluted EPS | $2.37 | Increased from $2.11 in Q1 2024 |
| Dividend Per Share | $0.60 | Increased from $0.53 in Q1 2024 |
| Net Cash from Operating Activities | $457.3M | Increased from $325.5M in Q1 2024 |
| Sleep and Breathing Health Revenue | $1.17B | Increased 9.5% from $1.07B in Q1 2024 |
| Residential Care Software Revenue | $166.1M | Increased 6.0% from $156.8M in Q1 2024 |
| Gross Profit | $820.8M | Increased 14.4% from $717.2M in Q1 2024 |
| Restructuring Expenses | $15.8M | New expense in Q1 2025, zero in Q1 2024 |
| Cash and Cash Equivalents | $1.38B | Increased from $1.21B at June 30, 2025 |
| FY2025 Revenue | $5.1B | Strong financial performance |
| FY2025 Free Cash Flow | $1.7B | Enabling investments and shareholder returns |
| Market Cap | $40B | As of July 31, 2025 |
Forward-Looking Statements
- {"claim":"Vanguard will maintain its passive investment strategy in ResMed Inc. without seeking active control.","entity":"The Vanguard Group","targetDate":"Ongoing","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Resmed Inc (RSMDF)?
Resmed Inc has 26 recent SEC filings from Jan 2024 to Nov 2025, including 13 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RSMDF filings?
Across 26 filings, the sentiment breakdown is: 3 bullish, 23 neutral. The dominant sentiment is neutral.
Where can I find Resmed Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Resmed Inc (RSMDF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Resmed Inc?
Key financial highlights from Resmed Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RSMDF?
The investment thesis for RSMDF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Resmed Inc?
Key executives identified across Resmed Inc's filings include Michael "Mick" Farrell, Christopher DelOrefice, Nicole Mowad-Nassar.
What are the main risk factors for Resmed Inc stock?
Of RSMDF's 24 assessed filings, 0 were flagged high-risk, 4 medium-risk, and 20 low-risk.
What are recent predictions and forward guidance from Resmed Inc?
Recent forward-looking statements from Resmed Inc include guidance on {"claim":"Vanguard will maintain its passive investment strategy in ResMed Inc. without seeking active control.","entity.